Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Sep;116(3):747-758.
doi: 10.1097/AOG.0b013e3181ee9fc7.

Benign breast disease

Mark D Pearlman  1 , Jennifer L Griffin
Affiliations
Review

Benign breast disease

Mark D Pearlman et al. Obstet Gynecol. 2010 Sep.

Abstract

Benign breast diseases are among the most common diagnoses that the busy obstetrician-gynecologist will see in practice. Moreover, breast cancer will undoubtedly be diagnosed numerous times in an obstetrician-gynecologist's career. An ability to accurately and promptly diagnose both benign and malignant breast diseases is within the purview of the generalist obstetrician-gynecologist. A thorough understanding of benign breast diseases, including appropriate diagnostic techniques, is vitally important in well-women care. In addition, a working knowledge of breast cancer risk factors with the ability to identify women at high risk and either refer or initiate risk reduction methods is equally important. This review outlines common benign breast diseases stratified by future risk of breast cancer and discusses appropriate management after diagnosis.

PubMed Disclaimer

References

    1. American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins—Gynecology, ACOG Committee of Genetics, Society of Gynecologic Oncologist. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009;113:957–66.
    1. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36–47.
    1. Anderson G, Limacher M, Assaf A, Bassford T, Beresford SAA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12.
    1. Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33.
    1. Heiss G, Wallace R, Anderson G, Aragaki A, Beresford SAA, Brzyski R, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036–45.

LinkOut - more resources